C₂N Diagnostics Releases PrecivityAD2™ Alzheimer’s Disease Blood Test For Clinical Care

C₂N Diagnostics released its PrecivityAD2 blood test for diagnosis of Alzheimer’s disease. It is a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests. This blood test is designed to help health care professionals evaluate consumers with signs and symptoms of Alzheimer’s disease and other causes of cognitive decline.

C₂N’s PrecivityAD2 blood test joins the company’s Precivity-ApoE blood test, which is indicated for use in adult patients for whom knowledge of apolipoprotein E2, E3, E4 allele status (indicating higher genetic risk of Alzheimer’s . . .